8
Participants
Start Date
November 30, 2012
Primary Completion Date
September 30, 2013
Study Completion Date
September 30, 2013
FGF-1 141
Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
FGF-1 141
Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
Dedicated Phase I, Phoenix
Lead Sponsor
Phage Pharmaceuticals, Inc.
INDUSTRY